Jaguar Health Inc. $(JAGX)$ has announced an extension of the maturity date for its convertible promissory notes from the recent bridge financing. The new maturity date is set for January 30, 2026, extending from the previous date of June 30, 2025. This change affects approximately $2.57 million in aggregate principal amount of the notes, which were part of a $3.448 million bridge financing deal that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million of the original financing into equity. CEO Lisa Conte expressed satisfaction with the agreement, highlighting the investors' commitment to supporting Jaguar's development programs for its plant-based medicine, crofelemer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。